Compare PRIM & BIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRIM | BIO |
|---|---|---|
| Founded | 1960 | 1952 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Water Sewer Pipeline Comm & Power Line Construction | Biotechnology: Laboratory Analytical Instruments |
| Sector | Industrials | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.8B | 7.2B |
| IPO Year | N/A | N/A |
| Metric | PRIM | BIO |
|---|---|---|
| Price | $166.01 | $269.15 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 4 |
| Target Price | $143.73 | ★ $358.50 |
| AVG Volume (30 Days) | ★ 653.9K | 297.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 0.20% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $20.64 | $1.50 |
| Revenue Next Year | $6.78 | $2.23 |
| P/E Ratio | $32.41 | ★ $9.52 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $49.10 | $211.43 |
| 52 Week High | $174.43 | $343.12 |
| Indicator | PRIM | BIO |
|---|---|---|
| Relative Strength Index (RSI) | 64.27 | 34.42 |
| Support Level | $161.12 | $251.00 |
| Resistance Level | $174.43 | $301.47 |
| Average True Range (ATR) | 8.49 | 10.83 |
| MACD | 0.49 | -3.55 |
| Stochastic Oscillator | 75.15 | 29.48 |
Primoris Services Corp is a provider of infrastructure services operating mainly in the United States and Canada. It provides a wide range of construction services, maintenance, replacement, fabrication and engineering services to a diversified base of customers. The reportable segments are the Utilities segment and the Energy segment. The Utilities segment operates in a range of services, including the installation and maintenance of new and existing natural gas and electric utility distribution and transmission systems, and communication systems. The Energy segment operates in a range of services that include engineering, procurement, and construction, retrofits, highway and bridge construction, demolition, site work, outages, pipeline construction and maintenance, and others.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.